SyntekaBio Inc Market Cap ($16.06 Million)
Market Cap & Net Worth: SyntekaBio Inc (226330)
SyntekaBio Inc market cap. SyntekaBio Inc (KQ:226330) has a market capitalization of $16.06 Million (₩23.70 Billion) as of November 5, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #25618 globally and #1898 in its home market, demonstrating a -11.58% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SyntekaBio Inc's stock price ₩977.00 by its total outstanding shares 24258475 (24.26 Million). Also see SyntekaBio Inc (226330) cash conversion ratio for how efficiently the company converts equity into cash flow.
SyntekaBio Inc Market Cap History (2020–2026)
SyntekaBio Inc market cap history from 2020 to 2026. Data shows change from $378.11 Million to $16.06 Million (-33.30% CAGR). Check 226330 live share price for real-time trading data and today's change.
Index Memberships
SyntekaBio Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$207.23 Billion | 0.01% | #1012 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$207.23 Billion | 0.01% | #1012 of 1384 |
Weight: SyntekaBio Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
SyntekaBio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SyntekaBio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 226330 net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.02x
SyntekaBio Inc's market cap is 0.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $378.11 Million | $609.68 Million | -$6.49 Billion | 0.62x | N/A |
| 2021 | $294.27 Million | $316.66 Million | -$14.80 Billion | 0.93x | N/A |
| 2022 | $141.05 Million | $243.99 Million | -$4.51 Billion | 0.58x | N/A |
| 2023 | $234.10 Million | $123.41 Million | -$11.40 Billion | 1.90x | N/A |
| 2024 | $86.31 Million | $120.89 Million | -$7.21 Billion | 0.71x | N/A |
| 2025 | $64.03 Million | $3.43 Billion | -$17.38 Billion | 0.02x | N/A |
Competitor Companies of 226330 by Market Capitalization
Companies near SyntekaBio Inc in the global market cap rankings as of November 5, 2026. Also see total assets of SyntekaBio Inc for a full breakdown of the balance sheet.
Key companies related to SyntekaBio Inc by market ranking:
- Veeva Systems Inc Class A (NYSE:VEEV): Ranked #725 globally with a market cap of $37.44 Billion USD.
- Pro Medicus Ltd (AU:PME): Ranked #1696 globally with a market cap of $13.94 Billion USD ( AU$19.71 Billion AUD).
- Tempus AI, Inc. Class A Common Stock (NASDAQ:TEM): Ranked #2023 globally with a market cap of $11.06 Billion USD.
- BrightSpring Health Services, Inc. Common Stock (NASDAQ:BTSG): Ranked #2082 globally with a market cap of $10.63 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #725 | Veeva Systems Inc Class A | NYSE:VEEV | $37.44 Billion | $310.63 |
| #1696 | Pro Medicus Ltd | AU:PME | $13.94 Billion | AU$188.64 |
| #2023 | Tempus AI, Inc. Class A Common Stock | NASDAQ:TEM | $11.06 Billion | $75.61 |
| #2082 | BrightSpring Health Services, Inc. Common Stock | NASDAQ:BTSG | $10.63 Billion | $69.80 |
Market Capitalization of SyntekaBio Inc (2020–2026)
Market capitalization of SyntekaBio Inc from 2020 to today. Between 2020 and today, SyntekaBio Inc's market cap moved from $378.11 Million to $ 16.06 Million, with a yearly change of -33.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩16.06 Million | -74.92% |
| 2025 | ₩64.03 Million | -25.81% |
| 2024 | ₩86.31 Million | -63.13% |
| 2023 | ₩234.10 Million | +65.97% |
| 2022 | ₩141.05 Million | -52.07% |
| 2021 | ₩294.27 Million | -22.17% |
| 2020 | ₩378.11 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of SyntekaBio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $16.06 Million USD |
| MoneyControl | $16.06 Million USD |
| MarketWatch | $16.06 Million USD |
| marketcap.company | $16.06 Million USD |
| Reuters | $16.06 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SyntekaBio Inc
SyntekaBio, Inc. operates as an artificial intelligence new drug development company based on genomic big data primarily in South Korea. It derives new drug candidates using DeepMatcher, an AI drug development platform that combines new drug development technology and genomic big data technology. The company also researches and develops biomarker detection for individual cancer drug screening, di… Read more